Advanced stage clear-cell epithelial ovarian cancer: the Hellenic Cooperative Oncology Group experience

Απλή σελίδα τεκμηρίου
dc.contributor.authorPectasides, D.en
dc.contributor.authorFountzilas, G.en
dc.contributor.authorAravantinos, G.en
dc.contributor.authorKalofonos, C.en
dc.contributor.authorEfstathiou, H.en
dc.contributor.authorFarmakis, D.en
dc.contributor.authorSkarlos, D.en
dc.contributor.authorPavlidis, N.en
dc.contributor.authorEconomopoulos, T.en
dc.contributor.authorDimopoulos, M. A.en
dc.date.accessioned2015-11-24T19:37:23Z
dc.date.available2015-11-24T19:37:23Z
dc.identifier.issn0090-8258-
dc.identifier.urihttps://olympias.lib.uoi.gr/jspui/handle/123456789/24024
dc.rightsDefault Licence-
dc.subjectAdenocarcinoma, Clear Cell/*drug therapy/pathology/surgeryen
dc.subjectAdulten
dc.subjectAgeden
dc.subjectAntineoplastic Combined Chemotherapy Protocols/*therapeutic useen
dc.subjectCarboplatin/administration & dosageen
dc.subjectCisplatin/administration & dosageen
dc.subjectCombined Modality Therapyen
dc.subjectCyclophosphamide/administration & dosageen
dc.subjectCystadenocarcinoma, Serous/*drug therapy/pathology/surgeryen
dc.subjectDoxorubicin/administration & dosageen
dc.subjectEpirubicin/administration & dosageen
dc.subjectFemaleen
dc.subjectHumansen
dc.subjectMiddle Ageden
dc.subjectNeoplasm Stagingen
dc.subjectOvarian Neoplasms/*drug therapy/pathology/surgeryen
dc.subjectPaclitaxel/administration & dosageen
dc.subjectRetrospective Studiesen
dc.subjectSurvival Rateen
dc.titleAdvanced stage clear-cell epithelial ovarian cancer: the Hellenic Cooperative Oncology Group experienceen
heal.abstractPURPOSE: Ovarian clear-cell carcinomas (OCCC) are known to be possibly resistant to platinum-based chemotherapy and to have a poorer prognosis with respect to other subtypes of epithelial ovarian cancer (EOC). This study was undertaken to compare response and survival to platinum-based chemotherapy between patients with advanced stage III and IV OCCC and serous EOC (sEOC). PATIENTS AND METHODS: A retrospective analysis was performed in patients with advanced stage of OCCC treated with first-line platinum-based chemotherapy in the context of several study protocols of the Hellenic Cooperative Oncology Group (HeCOG) between 1/2/1987 and 31/10/2003. The outcome was compared to that of patients with sEOC treated according to the same protocols during the same study period. RESULTS: One hundred and five patients (35 stage III and IV OCCC, 70 stage III and IV sEOC) treated with platinum-based chemotherapy were analyzed. The overall response rate for OCCC was 45% (complete response 25%) (95% CI, 23.1% to 68.5%) and 81% (complete response 46%) (95% CI, 67.4% to 91.1%) for sEOC. The overall response rate was significantly higher for sEOC (P = 0.008). In the subgroup of stage III patients, the rate of complete responders was higher among sEOC patients (P = 0.023). After a median follow-up of 61.1 months, median survival and time to tumor progression were not significantly different between the two groups (25.1 months [95% CI 11.7 to 38.5 months] versus 49.1 months [95% CI 36.5 to 61.6 months], P = 0.141, 12.0 months [95% CI 6.5 to 17.3 months] versus 18.0 months [95% CI 14.7 to 21.6 months], P = 0.384, respectively). CONCLUSION: Patients with OCCC have significantly lower response to platinum-based first-line chemotherapy compared to patients with sEOC. This low response to platinum-based chemotherapy was not translated in significantly shorter survival. The current study outcomes are provocative and suggest that a new strategy for chemotherapy in OCCC should be adopted, possibly one that focuses on new agents without cross-resistance to platinum agents.en
heal.accesscampus-
heal.fullTextAvailabilityTRUE-
heal.identifier.primary10.1016/j.ygyno.2005.12.038-
heal.identifier.secondaryhttp://www.ncbi.nlm.nih.gov/pubmed/16516283-
heal.identifier.secondaryhttp://ac.els-cdn.com/S0090825805011200/1-s2.0-S0090825805011200-main.pdf?_tid=3e9848d38435cab6a547c7f07b2c76ae&acdnat=1333613418_e738b98042bfb37ba643cbe05ac9a8de-
heal.journalNameGynecol Oncolen
heal.journalTypepeer-reviewed-
heal.languageen-
heal.publicationDate2006-
heal.recordProviderΠανεπιστήμιο Ιωαννίνων. Σχολή Επιστημών Υγείας. Τμήμα Ιατρικήςel
heal.typejournalArticle-
heal.type.elΆρθρο Περιοδικούel
heal.type.enJournal articleen

Αρχεία

Φάκελος/Πακέτο αδειών

Προβολή: 1 - 1 of 1
Μικρογραφία εικόνας
Ονομα:
license.txt
Μέγεθος:
1.74 KB
Μορφότυπο:
Item-specific license agreed upon to submission
Περιγραφή:
Κατεβάστε

Συλλογές

Άρθρα σε επιστημονικά περιοδικά ( Ανοικτά) - ΙΑΤ